Perrigo strengtheinging its niche Rx presence, acquires ophthalmic product portfolio from Fera pharmaceuticals

Perrigo Company will be acquiring ophthalmic sterile ointment and solution product portfolio from Fera Pharmaceuticals, LLC. Fera is a privately-held, Long Island, New York-based specialty pharmaceutical company.

 Transaction Valuation

Perigo would pay $93m in upfront payment and potential contingent payments totaling approximately $36 million, certain of which relate to Perrigo securing additional product rights from Fera. The acquired portfolio, including nine prescription ANDA products, generated more than $30 million in net revenues during calendar year 2012.  The deal values the portfolio at 3x revenue.

Additionally, Perrigo expects to receive a tax benefit as a result of the acquisition, the net present value of which is estimated to be approximately $20 million.